Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 56 of 58, showing 10 Applications out of 576 total, starting on record 551, ending on 560

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

551.

ECCT/25/08/06   MK-8527-010
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women   
Principal Investigator(s)
1. Irene Wambui Inwani
Site(s) in Kenya
1. UW-KNH; Rachuonyo County Hospital, Oyugis (Homa Bay county)
2. KEMRI-CMR-RCTP KEMRI CIS Building (Kisumu county)
3. Kargeno Research & Policy Hub (Kisumu county)
4. KEMRI-CCR-PHRD, Thika site (Kiambu county)
 
15-12-2025 View

552.

ECCT/25/08/07   ACCEDE Usability Study
    USABILITY, ACCEPTABILITY, FEASIBILITY AND COST OF CONTINUOUS GLUCOSE MONITORING BY PERSONS LIVING WITH TYPE 1 DIABETES MELLITUS, HEALTH CARE PROVIDERS AND CAREGIVERS AT THE PAEDIATRIC AND ADOLESCENT ENDOCRINOLOGY CLINIC IN KENYATTA NATIONAL HOSPITAL   
Principal Investigator(s)
1. Prisca Amolo
Site(s) in Kenya
Kenyatta National Hospital
 
10-12-2025 View

553.

ECCT/25/08/08   PROPS Trial
    Efficacy of probiotic supplementation in preterm and small for gestational age infants. A multi-centre, placebo-controlled, individually-randomised trial   (Probiotics in preterm and small for gestational age infants, PROPS trial)   
Principal Investigator(s)
1. Maureen Muchela
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Homabay County Referral Hospital (Homa Bay county)
3. Kisii Teaching and Referral Hospital (Kisii county)
4. Migori County Referral Hospital (Migori county)
 
29-04-2026 View

554.

ECCT/25/08/09   First-in-human (FIH) study
    A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Dr Lucas Tina Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute [VIBRI] (Kisumu county)
2. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county)
 
17-09-2026 View

555.

ECCT/25/09/01   VLA1553-404
    VLA1553-404: A Pragmatic Randomised Controlled Trial to Evaluate the Effectiveness and Safety of VLA1553 against Chikungunya Virus Disease   
Principal Investigator(s)
1. Prof. Videlis Nduba
Site(s) in Kenya
1. KEMRI-MTWAPA (Kilifi county)
 
21-01-2026 View

556.

ECCT/25/09/03   PRESERVE
    Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study   
Principal Investigator(s)
1. Angela Waweru
Site(s) in Kenya
Aga Khan University Hospital
 
09-02-2026 View

557.

ECCT/25/10/01   H06_04TP
    A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years   after vaccination in African children.   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
KEMRI CRC WRP KERICHO
 
01-02-2026 View

558.

ECCT/25/11/01   COMBO-CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr. Wilson Muraya
Site(s) in Kenya
1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county)
2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county)
3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county)
 
21-06-2026 View

559.

ECCT/25/11/02   DELIVER-02
    IGHID 12430/DELIVER-02 - A PHASE 1, OPEN LABEL,STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF MGD014 AND MGD020 WITH A LATENCY REVERSAL AGENT VERSUS TEMPORARY TREATMENT INTERRUPTION IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
1. Kericho Clinical Research Center (Kericho CRC), Kericho, (Kericho county)
2. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (MUCRC), ELDORET (Uasin Gishu county)
 
25-06-2026 View

560.

ECCT/25/11/03   RSV IMPACT TRIAL
    A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants.   
Principal Investigator(s)
1. Nancy A. Otieno
2. Evans M. Ogoti
Site(s) in Kenya
Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1)
 
09-02-2026 View